ARCHIVES

In Brief: Schweitzer ACS President, Dodd President Elect, FDA Commissioner Resigns Abruptly

This article is from The Cancer Letter archive.

Vol. 15 No. 44 | November 17, 1989

Download PDF Visit The Full Archive

Related Articles

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

July 26, 2002

Cooperative Group Leadership Changes: Decosse Heads CCIRC, Hoogstraten Chairmen’s Committee

July 8, 1977

NCI Study Says 2 Million US Women Could Benefit from Tamoxifen

April 11, 2003

Survival For ALL Increased To 94 Percent In Recent Years

December 31, 2010

Bloch Dissatisfied With PDQ, Offers $1 Million To fund “Tailored” Treatment Data To Physicians

November 13, 1987

NCI Names Brawly Director of Office of Special Populations

June 21, 1996